Abstract 1686P
Background
As global cancer cases increase exponentially, the number of caregivers subsequently increases to support patients. Despite being indispensable, the available resource was reserved mainly for patients, undermining the importance of caregivers who also share the struggle and burden. The chronic amount of stress and responsibility that caregivers face leads to impairment of quality of life (QOL). Further, most research that assesses the QOL is mainly conducted in the developed countries with robust palliative care. This comparative study aims to map and explore the status quo of QOL levels from caregivers of cancer patients in Asia. In addition, to investigate the correlation of QOL impairments in caregivers with sociodemographic factors.
Methods
A comprehensive systematic review of the literature was performed through databases with the keywords “cancer”, “caregiver”,” quality of life”, and “Asia” spans from 2004-2024. 371 articles that satisfy eligible criteria were retrieved. A total of 1271 family caregivers for cancer patients who had taken outpatient treatment, finished sociodemographic, and the Caregiver Quality of Life Index-Cancer (CQOLC) survey were included. Gathered CQOLC total scores from 12 countries including Indonesia, Singapore, Malaysia, Turkey, Iran, Jordanian, India, South Korea, China, Taiwan, Japan, and Saudi Arabia dataset, were compared and analyzed for their correlation with sociodemographic factors.
Results
Different distributions of total scores of CQOLC in 12 Asia countries observed with higher CQOLC total scores were scored within the developed countries with mature palliative care systems. Further, varying caregiver determinants including different sociodemographic characteristics could produce impaired QOL such as male gender, parental relationships, certain ethnicity, and late-stage cancer.
Conclusions
Despite sharing cultural context and family-based caregivers, uneven QOL distribution was observed across Asian countries. This study also highlights the potential areas to be improved. Additionally, acknowledging the diversity of values, culture, and socio-demographics significantly helps in creating more optimal interventions to support caregivers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11